A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Kim, D-W. [1 ,2 ]
Lee, S-H. [3 ]
Jang, I-J. [4 ]
Park, K-J. [5 ]
Lee, D. H. [6 ]
机构：
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea
[4] Seoul Univ Hosp, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
[5] CKD Chong Kun Dang Res Inst Hyojong, Bio Drug Discovery, Yongin, South Korea
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
998P
引用
收藏
页码：S1010 / S1010
页数：1
相关论文
共 50 条
  • [21] Gemcitabine in locally advanced and metastatic non-small cell lung cancer (NSCLC): The Central European phase II study
    Jassem, J
    Zatloukal, P
    Kanitz, E
    Magyar, P
    Krzakowski, M
    Pawlicki, M
    Petruzelka, L
    Chovan, L
    Pesek, M
    Krejcy, K
    ANNALS OF ONCOLOGY, 1998, 9 : 90 - 90
  • [22] Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC).
    Gauler, Thomas Christoph
    Besse, Benjamin
    Novello, Silvia
    Smit, Egbert F.
    Plummer, Elizabeth R.
    Delord, Jean-Pierre
    Nicodemo, Maurizio
    Santoro, Armando
    Barone, Carlo
    Marchetti, Paolo
    Conte, Pier Franco
    De Jonge, Maja J.
    Awada, Ahmad
    Mariani, Mariangela
    Jannuzzo, Maria Gabriella
    Petroccione, Anna
    Ceruti, Roberta
    Davite, Cristina
    Eberhardt, Wilfried Ernst Erich
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC).
    Rowlands, Tracey
    Boyapati, Anita
    Li, Siyu
    Daly, Christopher
    Seebach, Frank A.
    Lowy, Israel
    Rietschel, Petra
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)
    Reck, M
    ANTICANCER RESEARCH, 2005, 25 (3A) : 1501 - 1506
  • [25] Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Kim, C.
    Liu, S.
    Subramaniam, D.
    Giaccone, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S479 - S479
  • [26] Phase 2 study of bortezomib±docetaxel in advanced non-small cell lung cancer (NSCLC)
    Fanucchi, M
    Fossella, F
    Fidias, P
    Natale, R
    Belt, R
    Govindan, R
    Raez, L
    Schiller, J
    Kashala, O
    Kelly, K
    LUNG CANCER, 2005, 49 : S30 - S30
  • [27] Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC).
    Mauer, AM
    Otterson, G
    Rudin, CM
    Villalona, M
    Ansari, RH
    Szeto, L
    Vokes, EE
    CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
  • [28] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [29] Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
    Gray, Jhanelle E.
    Saltos, Andreas
    Tanvetyanon, Tawee
    Haura, Eric B.
    Creelan, Ben
    Antonia, Scott J.
    Shafique, Michael
    Zheng, Hong
    Dai, Wenjie
    Saller, James J.
    Chen, Zhihua
    Tchekmedyian, Nishan
    Goas, Kristen
    Thapa, Ram
    Boyle, Theresa A.
    Chen, Dung-Tsa
    Beg, Amer A.
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6623 - 6632
  • [30] Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
    Tan, Aaron C.
    Teh, Yi Lin
    Lai, Gillianne G. Y.
    Tan, Daniel S. W.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 431 - 435
12345